Elekta AB Series B Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 6/4/2026)
| Balance Sheet | Total Assets | 26,955,000,000.00 | ROE | 26.34 % |
| Balance Sheet | Total Equity | 7,099,000,000.00 | ROA | -1.93 % |
| Cashflow | Capital Expenditures | -120,000,000.00 | P/FCF | 9.05 |
| Cashflow | Free Cash Flow | 2,344,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 2,464,000,000.00 | P/CF | 8.61 |
| Income | Earnings per Share (diluted) | -1.36 | Div. Yield | 4.32 % |
| Income | Net Income | -520,000,000.00 | P/E | -40.66 |
| Income | Shares Outstanding | 383,559,000.00 | P/B | 2.99 |
| Income | Total Revenue | 16,718,000,000.00 | P/S | 1.27 |
Ratios calculated on: 10/14/2026
Company Description
Elekta AB develops, manufactures and sells treatment planning systems for neurosurgery and radiation therapy, including stereotactic radiation surgery and brachytherapy. The company's installed base with more than 4,500 platforms and software is used in more than 6,000 hospitals worldwide. The company's sales are evenly distributed across the regions, with North and South America accounting for 31%; Europe, the Middle East and Africa account for 38%; and Asia Pacific contributed the rest.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.elekta.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more